Eliminating The Public Health Problem Of Hepatitis B And C In The United States Phase One Report 1st Edition Medicine Engineering National Academies Of Sciences Health And Medicine Division Board On Population Health And Public Health Practice Committee On A National Strategy For The Elimination Of Hepatitis B And C Brian L Strom Gillian J Buckley by Medicine Engineering National Academies Of Sciences; Health And Medicine Division; Board On Population Health And Public Health Practice; Committee On A National Strategy For The Elimination Of Hepatitis B And C; Brian L. Strom; Gillian J. Buckley 9780309438001, 0309438004 instant download after payment.

Hepatitis B and C cause most cases of hepatitis in the United States and the world. The two diseases account for about a million deaths a year and 78 percent of world's hepatocellular carcinoma and more than half of all fatal cirrhosis. In 2013 viral hepatitis, of which hepatitis B virus (HBV) and hepatitis C virus (HCV) are the most common types, surpassed HIV and AIDS to become the seventh leading cause of death worldwide. The world now has the tools to prevent hepatitis B and cure hepatitis C. Perfect vaccination could eradicate HBV, but it would take two generations at least. In the meantime, there is no cure for the millions of people already infected. Conversely, there is no vaccine for HCV, but new direct-acting antivirals can cure 95 percent of chronic infections, though these drugs are unlikely to reach all chronically-infected people anytime soon. This report, the first of two, examines the feasibility of hepatitis B and C elimination in the United States and identifies critical success factors. The phase two report will outline a strategy for meeting the elimination goals discussed in this report.